{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:37:11Z","timestamp":1790519831179,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is no effective medical treatment for oral precancer, and surgery to remove these lesions is imprecise because abnormal mucosa extends beyond the visible lesion. Development of vectors for tumor-selective viral replication has been a significant advance, and viral lysis is well suited to destruction of oral precancerous mucosa. To facilitate evaluation of new treatments, we engineered dysplastic oral epithelium using keratinocytes isolated from dysplastic lesions. We show that these model systems recapitulate the key characteristics of the clinical lesions closely, and that topical delivery of the conditionally replicating adenovirus (CRAd) dl922-947 can lyse tissue-engineered epithelia that show mild, moderate, or severe dysplasia, but normal oral epithelia are very resistant to this treatment. The lytic effect is determined by various factors, including the grade and proliferation index of the dysplastic epithelia. The presence of suprabasal cycling cells, expression of the coxsackie adenovirus receptor (CAR), the transcription cofactor p300, and other aberrations that affect the regulation of the cell cycle or apoptosis and promote viral replication may also be important. The ability of dl922-947 to destroy engineered oral dysplasia was significantly greater than that observed using wild-type adenovirus, d\/1520, or viruses modified to bypass cell entry dependent on the presence of CAR. Evidence of infection in clinical dysplastic lesions was also shown ex vivo using tissue explants. We conclude that dl922-947 may provide an efficient molecular cytotoxic to dissolve oral dysplastic lesions. [Cancer Res 2007;67(15):7284\u201394]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3834","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T18:34:13Z","timestamp":1185993253000},"page":"7284-7294","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lysis of Dysplastic but not Normal Oral Keratinocytes and Tissue-Engineered Epithelia with Conditionally Replicating Adenoviruses"],"prefix":"10.1158","volume":"67","author":[{"given":"Kamis","family":"Gaballah","sequence":"first","affiliation":[{"name":"1Head and Neck Cancer Unit, King's College London, Guy's, King's and St. Thomas' Hospitals, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Hills","sequence":"additional","affiliation":[{"name":"1Head and Neck Cancer Unit, King's College London, Guy's, King's and St. Thomas' Hospitals, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Curiel","sequence":"additional","affiliation":[{"name":"3Division of Human Gene Therapy, University of Alabama at Birmingham, Birmingham, Alabama; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnel","family":"Hallden","sequence":"additional","affiliation":[{"name":"2Centre for Molecular Oncology, Institute of Cancer and the Cancer Research United Kingdom Clinical Centre, Barts and The London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harrison","sequence":"additional","affiliation":[{"name":"4Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Partridge","sequence":"additional","affiliation":[{"name":"1Head and Neck Cancer Unit, King's College London, Guy's, King's and St. Thomas' Hospitals, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2022061623335457200_B1","doi-asserted-by":"crossref","unstructured":"Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res\u20081996; 56: 2488\u201392.","DOI":"10.1016\/S0194-5998(96)80631-0"},{"key":"2022061623335457200_B2","doi-asserted-by":"crossref","unstructured":"Partridge M, Emilion G, Pateromichelakis S, Phillips E, Langdon J. Field cancerization of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol\u20081997; 33: 332\u20137.","DOI":"10.1016\/S1368-8375(97)00035-3"},{"key":"2022061623335457200_B3","doi-asserted-by":"crossref","unstructured":"Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP, Langdon JD. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol\u20081998; 34: 77\u201383.","DOI":"10.1016\/S1368-8375(97)00052-3"},{"key":"2022061623335457200_B4","unstructured":"Partridge M, Pateromichelakis S, Phillips E, et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res\u20082000; 60: 3893\u20138."},{"key":"2022061623335457200_B5","doi-asserted-by":"crossref","unstructured":"van Houten VM, Leemans CR, Kummer JA, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res\u20082004; 10: 3614\u201320.","DOI":"10.1158\/1078-0432.CCR-03-0631"},{"key":"2022061623335457200_B6","doi-asserted-by":"crossref","unstructured":"Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoural efficacy. Nat Med\u20082000; 6: 1134\u20139.","DOI":"10.1038\/80474"},{"key":"2022061623335457200_B7","doi-asserted-by":"crossref","unstructured":"Fueyo J, Gomes-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene\u20082000; 19: 2\u201312.","DOI":"10.1038\/sj.onc.1203251"},{"key":"2022061623335457200_B8","unstructured":"Li D, Duan L, Freimuth P, O'Malley BW. Variability of adenovirus receptor density influences gene transfer efficacy and therapeutic response in head and neck cancer. Clin Cancer Res\u20081999; 5: 4175\u201381."},{"key":"2022061623335457200_B9","unstructured":"Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res\u20082001; 61: 813\u20137."},{"key":"2022061623335457200_B10","doi-asserted-by":"crossref","unstructured":"Hamidi S, Salo T, Kainulainen T, et al. Expression of \u03b1(v)\u03b26 integrin in oral leukoplakia. B J Cancer\u20082000; 82: 1433\u201340.","DOI":"10.1054\/bjoc.1999.1130"},{"key":"2022061623335457200_B11","doi-asserted-by":"crossref","unstructured":"Regezi JA, Ramos DM, Pytela R, Dakker NP, Jordan RC. Tenascin and \u03b26 integrin are overexpressed in floor of the mouth in situ carcinomas. Oral Oncol\u20082002; 38: 332\u20136.","DOI":"10.1016\/S1368-8375(01)00062-8"},{"key":"2022061623335457200_B12","unstructured":"Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res\u20082001; 7: 120\u20136."},{"key":"2022061623335457200_B13","unstructured":"Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT, Blackwell JL. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res\u20082003; 63: 1262\u20139."},{"key":"2022061623335457200_B14","doi-asserted-by":"crossref","unstructured":"Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol\u20082004; 78: 4454\u201362.","DOI":"10.1128\/JVI.78.9.4454-4462.2004"},{"key":"2022061623335457200_B15","doi-asserted-by":"crossref","unstructured":"Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology\u20082004; 322: 349\u201359.","DOI":"10.1016\/j.virol.2004.02.016"},{"key":"2022061623335457200_B16","doi-asserted-by":"crossref","unstructured":"Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an EI B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med\u20081997; 3: 639\u201345.","DOI":"10.1038\/nm0697-639"},{"key":"2022061623335457200_B17","doi-asserted-by":"crossref","unstructured":"McCormick F. ONYX-015 selectivity and the p14ARF pathway. Oncogene\u20082000; 19: 6670\u20132.","DOI":"10.1038\/sj.onc.1204096"},{"key":"2022061623335457200_B18","doi-asserted-by":"crossref","unstructured":"Reis SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumour cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med\u20082000; 6: 1128\u201333.","DOI":"10.1038\/80466"},{"key":"2022061623335457200_B19","doi-asserted-by":"crossref","unstructured":"Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol\u20082003; 21: 4546\u201352.","DOI":"10.1200\/JCO.2003.03.544"},{"key":"2022061623335457200_B20","doi-asserted-by":"crossref","unstructured":"Wang Y, Thorne S, Hannock J, et al. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res\u20082005; 11: 351\u201360.","DOI":"10.1158\/1078-0432.351.11.1"},{"key":"2022061623335457200_B21","doi-asserted-by":"crossref","unstructured":"Partridge M, Green MR, Langdon JD, Feldmann M. Production of TGF-\u03b1 and TGF-\u03b2 by cultured keratinocytes, skin and oral squamous cell carcinomas\u2014potential autocrine regulation of normal and malignant epithelial cell proliferation. Br J Cancer\u20081989; 60: 542\u20138.","DOI":"10.1038\/bjc.1989.310"},{"key":"2022061623335457200_B22","unstructured":"McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res\u20082002; 62: 4757\u201366."},{"key":"2022061623335457200_B23","doi-asserted-by":"crossref","unstructured":"Chang SE, Foster S, Betts D, et al. DOK, a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype. Int J Cancer\u20081992; 52: 896\u2013902.","DOI":"10.1002\/ijc.2910520612"},{"key":"2022061623335457200_B24","doi-asserted-by":"crossref","unstructured":"Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also bypass a p16 (INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol\u20082000; 20: 1436\u201347.","DOI":"10.1128\/MCB.20.4.1436-1447.2000"},{"key":"2022061623335457200_B25","doi-asserted-by":"crossref","unstructured":"Easty DM, Easty GC, Carter RL, Monaghan P, Butler LJ. Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer\u20081981; 43: 772\u201385.","DOI":"10.1038\/bjc.1981.115"},{"key":"2022061623335457200_B26","doi-asserted-by":"crossref","unstructured":"Igarashi M, Irwin CR, Locke M. Mackenzie IC. Construction of large area organotypical cultures of oral mucosa and skin. J Oral Pathol Med\u20082003; 32: 422\u201330.","DOI":"10.1034\/j.1600-0714.2003.00090.x"},{"key":"2022061623335457200_B27","unstructured":"Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res\u20082002; 62: 3812\u20138."},{"key":"2022061623335457200_B28","unstructured":"Partridge M, Smith CG, Green MR. Differences between the distribution of epidermal growth factor receptor in human skin and oral mucosa, detected by immunohistology and EGF binding studies. Epithelia\u20081988; 1: 179\u201390."},{"key":"2022061623335457200_B29","doi-asserted-by":"crossref","unstructured":"Thompson PJ, Soames JV, Booth C, O'Shea JA. Epithelial cell proliferative activity and oral cancer progression. Cell Prolif\u20082002; 35: 110\u201320.","DOI":"10.1046\/j.1365-2184.35.s1.12.x"},{"key":"2022061623335457200_B30","doi-asserted-by":"crossref","unstructured":"Stark H-J, Wilhauck MJ, Mirancea N, et al. Authentic fibroblast matrix in dermal equivalents normalises epidermal histogenesis and dermo-epidermal junction in organotypic co-culture. Eur J Cell Biol\u20082004; 83: 631\u201345.","DOI":"10.1078\/0171-9335-00435"},{"key":"2022061623335457200_B31","doi-asserted-by":"crossref","unstructured":"Papadimitrakopoulou V, Izzo J, Lippman SMG, et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene\u20081997; 14: 1799\u2013803.","DOI":"10.1038\/sj.onc.1201010"},{"key":"2022061623335457200_B32","doi-asserted-by":"crossref","unstructured":"Shintani S, Mihara M, Nakahara Y, et al. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol\u20082002; 38: 235\u201343.","DOI":"10.1016\/S1368-8375(01)00048-3"},{"key":"2022061623335457200_B33","doi-asserted-by":"crossref","unstructured":"Oliver RJ, MacDonald DG. G1 cyclins in oral epithelial dysplasia. J Oral Pathol Med\u20082001; 30: 80\u20136.","DOI":"10.1034\/j.1600-0714.2001.300203.x"},{"key":"2022061623335457200_B34","doi-asserted-by":"crossref","unstructured":"Howe JA, Bayley ST. Effects of AdE1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. Virology\u20081992; 196: 15\u201324.","DOI":"10.1016\/0042-6822(92)90057-V"},{"key":"2022061623335457200_B35","doi-asserted-by":"crossref","unstructured":"Goodman RH, Smolik S. CBP\/p300 in cell growth, transformation and development. Genes Dev\u20082000; 14: 1553\u201377.","DOI":"10.1101\/gad.14.13.1553"},{"key":"2022061623335457200_B36","doi-asserted-by":"crossref","unstructured":"Berk AJ. Lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene\u20082005; 24: 7673\u201385.","DOI":"10.1038\/sj.onc.1209040"},{"key":"2022061623335457200_B37","doi-asserted-by":"crossref","unstructured":"Lockley M, Fernandez M, Wang Y. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild type viruses, bioluminescence monitoring and intraperitoneal delivery in icodextrin. Cancer Res\u20082005; 6: 989\u201398.","DOI":"10.1158\/0008-5472.CAN-05-2691"},{"key":"2022061623335457200_B38","doi-asserted-by":"crossref","unstructured":"Noya F, Balague C, Banerjee NS, Curiel DT, Broker TR, Chow LT. Activation of adenovirus early promoters and lytic phase in differentiated strata of organotypic cultures of human keratinocytes. J Virol\u20082003; 77: 6533\u201340.","DOI":"10.1128\/JVI.77.11.6533-6540.2003"},{"key":"2022061623335457200_B39","doi-asserted-by":"crossref","unstructured":"O'Shea CC, Johnson L, Bague B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-O15 tumour selectivity. Cancer Cell\u20082004; 6: 611\u201323.","DOI":"10.1016\/j.ccr.2004.11.012"},{"key":"2022061623335457200_B40","doi-asserted-by":"crossref","unstructured":"Banoczy J, Squier CA, Kremer M, et al. The permeability of oral leukoplakia. Eur J Oral Sci\u20082003; 111: 312\u20135.","DOI":"10.1034\/j.1600-0722.2003.00042.x"},{"key":"2022061623335457200_B41","doi-asserted-by":"crossref","unstructured":"Ikarashi T, Yonemochi H, Ohshiro K, Cheng J, Saku T. Intraepithelial expression of perlecan, a basement membrane-type heparan sulphate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med\u20082004; 33: 87\u201395.","DOI":"10.1111\/j.1600-0714.2004.00026.x"},{"key":"2022061623335457200_B42","doi-asserted-by":"crossref","unstructured":"Prime SS, Pitigala-Arachchi A, Crane IJ. The expression of cell surface MHC class I heavy and light chain molecules in pre-malignant and malignant lesions of the oral mucosa. Histopathology\u20081987; 11: 81\u201391.","DOI":"10.1111\/j.1365-2559.1987.tb02611.x"},{"key":"2022061623335457200_B43","doi-asserted-by":"crossref","unstructured":"Stenenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol\u20081997; 71: 2782\u201390.","DOI":"10.1128\/jvi.71.6.4782-4790.1997"},{"key":"2022061623335457200_B44","doi-asserted-by":"crossref","unstructured":"Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther\u20082002; 13: 1647\u201353.","DOI":"10.1089\/10430340260201734"},{"key":"2022061623335457200_B45","doi-asserted-by":"crossref","unstructured":"Kaneva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther\u20082003; 8: 1\u201310.","DOI":"10.1016\/S1525-0016(03)00200-4"},{"key":"2022061623335457200_B46","doi-asserted-by":"crossref","unstructured":"Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenoviral vector via replacement of the fibre protein with the phage T4 fibritin. J Virol\u20082001; 75: 4176\u201383.","DOI":"10.1128\/JVI.75.9.4176-4183.2001"},{"key":"2022061623335457200_B47","doi-asserted-by":"crossref","unstructured":"Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fibre protein. J Virol\u20082003; 76: 8621\u201331.","DOI":"10.1128\/JVI.76.17.8621-8631.2002"},{"key":"2022061623335457200_B48","doi-asserted-by":"crossref","unstructured":"Borovjagin AV, Krendelchtchikov A, Ramesh N, Yu D-C, Douglas JT, Curiel DT. Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors. Cancer Gene Ther\u20082005; 12: 475\u201386.","DOI":"10.1038\/sj.cgt.7700806"},{"key":"2022061623335457200_B49","doi-asserted-by":"crossref","unstructured":"Stoff A, Rivera AA, Banerjee NS, et al. Strategies to enhance transduction efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair Regen\u20082006; 14: 608\u201317.","DOI":"10.1111\/j.1743-6109.2006.00168.x"},{"key":"2022061623335457200_B50","doi-asserted-by":"crossref","unstructured":"Tyler MA, Ulasov IV, Borovjagin A, et al. Enhanced transduction of malignant glioma with a double targeted Ad5\/3-RGD fibre-modified adenovirus. Mol Cancer Ther\u20082006; 5: 2408\u201316.","DOI":"10.1158\/1535-7163.MCT-06-0187"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7284\/2866085\/7284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7284\/2866085\/7284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T17:00:29Z","timestamp":1683997229000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/15\/7284\/533290\/Lysis-of-Dysplastic-but-not-Normal-Oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":50,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3834","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}